Glioma

The presence of a hemizygous CDKN2A/B deletion occurs more frequently in astrocytomas compared to oligodendrogliomas at the time of primary diagnosis. Worse survival in patients with astrocytoma and CDKN2A/B hemizygous loss was observed, specifically in WHO grade 2, but this prognostic effect disappeared when adjusting for clinical factors.

Astrocyte-derived VCAM1 is a critical driver of glioma progression, mediating essential interactions between tumor cells and the TME. Targeting VCAM1 signaling presents a promising, microenvironment-focused therapeutic strategy, though its clinical application must account for regional and genetic tumor heterogeneity.

All results significantly exceeded the performance of conventional CEST quantification techniques and existing deep learning-based models developed for CEST analysis (p < 0.05). MixBranchNet establishes a methodological foundation for spatial-spectral deep learning in CEST MRI and demonstrates encouraging performance for glioma segmentation and genotype prediction within the current single-center cohort.

P=N/A, N=71, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting

P2, N=39, Not yet recruiting, Clinica Universidad de Navarra, Universidad de Navarra

P=N/A, N=500, Recruiting, Poitiers University Hospital | Trial completion date: Jun 2026 --> Feb 2029 | Trial primary completion date: Jun 2026 --> Feb 2029

P1, N=30, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2026 --> May 2027

Our data reveal a pro-oncogenic role of RPS5 in glioma progression and highlight its critical function in regulating translation. These findings provide new evidence supporting the central role of ribosome protein-induced translational dysregulation in cancer and offer innovative perspectives for developing molecular therapies targeting GBM.

We explore therapeutic implications, from promoting reparative angiogenesis in ischemia to inhibiting pathological angiogenesis in glioblastoma. By identifying critical knowledge gaps, we propose future directions-such as astrocyte-specific gene editing and engineered exosomes-that aim to translate these insights into effective, context-specific CNS therapies.

Because BRAF alterations are observed in most pilocytic astrocytomas, treatments targeting the MAPK pathway play an important role in the management of optic gliomas. Inhibition of the MAPK signaling pathway represents a potential advance in the treatment of optic gliomas.

P2, N=48, Recruiting, Case Comprehensive Cancer Center | Initiation date: Aug 2025 --> Mar 2026

This study identifies bulk transcriptome-defined groups and reveals EGFR-associated malignant cell programs linked to distinct microenvironmental interaction patterns. The EGFR-high malignant cell state features proliferative and angiogenic programs, while the EGFR-low malignant cell state shows enhanced immune infiltration. These findings provide molecular evidence for precision classification and subtype-specific therapeutic strategies.